Kiora Pharmaceuticals has obtained exclusive development and commercialization rights outside Asia to KIO-401 (mitucapistat), an investigational oral calpain inhibitor for central retinal artery occlusion (CRAO), from Senju Pharmaceutical. The company plans to initiate a multinational phase 3 registration trial in CRAO in 2027 and expand development into nonarteritic anterior ischemic optic neuropathy (NAION). Announcing the agreement, Shuhei Yoshida, president and CEO of Senju Pharmaceutical, said, “The clinical results generated in Japan support continued global development of this compound as a potential treatment for acute retinal ischemia.” Senju has completed phase 2a and phase 3 clinical studies of the compound, designated SJP-0008 in Japan.
Filter by:
Eyewire News
Jordan Deaner, MD; Collin Richards, MD; Erik Massenzio, MD; Justin C. Muste, MD; and David Fell, MD
Eyetube
Levent Akduman, MD, and Lauren Pollack, BS
Ahmed Abdelshafy Tabl, MD
Maria Berrocal, MD and Yoshi Yonekawa, MD
Kevin J. Corcoran, COE, CPC, CPMA, FNAO
View More
New Retina Radio is a place to hear stories about retina that are told nowhere else.
The RETINAWS panel led by Kourous Rezaei, MD, discuss techniques for vitreoretinal surgery and rare surgical cases.
%20(1)_1793732257.JPG?auto=compress,format&w=400)
Eyewire headlines are now available as a weekly podcast! Listen Now